COVID-19 alert: Read about changed restrictions for businesses in Greater Brisbane from 6pm, Monday 11 January.
PlasProtecT® whole parasite malaria vaccine
PlasProtecT® is a chemically attenuated, whole parasite, blood stage malaria vaccine candidate.
Unique selling point/competitive advantage
PlasProtecT® has a demonstrated ability to elicit cross-strain and cross-species protective immune response in rodent models. It has also been demonstrated to be immunogeneic in first-in-man clinical studies.
As a whole parasite malaria vaccine, PlasProtecT® has the potential to address the lack of cross-strain protection associated with sub-unit vaccines. A human challenge model has also been developed at Griffith University.
Investment or collaboration opportunities
Griffith University is seeking partners to co-develop or sponsor clinical development of PlasProtecT®. Contact Griffith University to discuss your interest in exclusive licensing and co-development opportunities.
Intellectual property rights
Patent application under Patent Cooperation Treaty (PCT) has been filed.
Dr Chris Davis
General Manager, Institute for Glycomics
Phone: +61 7 5552 7033
Visit Griffith University's Institute for Glycomics for more information.
- Last reviewed: 17 Jul 2019
- Last updated: 30 May 2018